Enanta Pharmaceuticals Inc (ENTA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Enanta Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 13.00 $ — 63% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
0/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -3.3%
- Exp. sales growth 3Y > 5% 1.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 1.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 4
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -126.5%
- ROCE > 15% -36.8%
- Expected return > 10% -8.0%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -8.8% failed
- More than 10% revenue growth is expected for the coming year 0.3% failed
- Share count grows by less than 3% a year 1.2% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -52.7% failed
- Gross margin at 40% or higher and without meaningful erosion 93.0% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 131 m failed
- Return on capital at 15% or higher, or up versus two years ago -36.8% failed
- Insiders hold at least 10% or are net buyers 4.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 62.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 09/30/2026 | -1.88 | -2.27 – -1.39 | 66 | 51.0% | 4 |
| 09/30/2027 | -2.05 | -3.08 – -1.31 | 67 | -8.9% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.37 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.05 | – | 17 | -5.80 | -131.40 | -17 | -26 |
| 2025: Q1 | -1.06 | – | 15 | -12.50 | -151.70 | -14 | -16 |
| 2025: Q2 | -0.86 | – | 18 | 1.90 | -99.70 | 18 | 17 |
| 2025: Q3 | -0.87 | – | 15 | 3.50 | -123.60 | -7 | -8 |
| 2025: Q4 | -0.56 | – | 19 | 9.80 | -64.10 | -12 | -12 |
| 2026: Q1 | -0.61 | – | 17 | 15.00 | -76.30 | -7 | -7 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 88 | 31 | 22 | 1.13 | 36 | 270 | 281 |
| 2017 | 103 | 25 | 18 | 0.91 | 53 | 302 | 327 |
| 2018 | 207 | 88 | 72 | 3.48 | 29 | 394 | 414 |
| 2019 | 205 | 37 | 46 | 2.21 | 71 | 462 | 490 |
| 2020 | 122 | -42 | -36 | -1.81 | 7 | 456 | 491 |
| 2021 | 97 | -110 | -79 | -3.92 | -70 | 399 | 441 |
| 2022 | 86 | -124 | -122 | -5.91 | -85 | 321 | 381 |
| 2023 | 79 | -137 | -134 | -6.38 | -103 | 217 | 462 |
| 2024 | 68 | -122 | -116 | -5.48 | -79 | 129 | 377 |
| 2025 | 65 | -85 | -82 | -3.84 | -19 | 65 | 281 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Enanta Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
| Employees | 120 |
|---|---|
| Headquarters | Watertown, MA |
| Address | 4 Kingsbury Avenue, 02472 Watertown, United States |
| Phone | 617 607 0800 |
| Website | enanta.com |
| IPO Date | 21. Mar 2013 |
| ISIN | US29251M1062 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jay R. Luly Ph.D. | President, CEO & Director | 1956 |
| Yat Sun Or Ph.D. | Chief Scientific Officer | 1952 |
| Scott T. Rottinghaus M.D. | Chief Medical Officer | 1974 |
| Harry R. Trout III | VP of Finance & Interim Principal Financial Officer | 1969 |
| Kathleen S. Capps CPA | Executive Director of Accounting, Controller & Interim Principal Accounting Officer | 1985 |
| Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | – |
| Matthew P. Kowalsky J.D. | Chief Legal Officer & Corporate Secretary | 1973 |
| Nathaniel S. Gardiner J.D. | Consultant | 1954 |
| Tara Lynn Kieffer Ph.D. | Chief Product Strategy Officer | 1978 |
| Brendan Luu | Chief Business Officer | 1975 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.